Is this your firm? Get featured or correct your listing →
At a glance
Casdin Capital appears in 3 funding rounds tracked by ValueAddVC since 2026. Its most frequent sector in these rounds is Health & Biotech, and its most recent tracked deal was Atrium Therapeutics' $50M round (Oct 10, 2026).
Strategy
Recent changes
- Oct 10, 2026Oct 10, 2026Invested in Atrium Therapeutics ($50M) Pulse 2.0
- Oct 6, 2026Oct 6, 2026Invested in Multiply Labs (Series B, $75M) Business Wire
- Jun 30, 2026Jun 30, 2026Invested in Flare Therapeutics (Series C, $85M) GlobeNewswire
Portfolio
3 totalRecent Investment Activity
3Track record: led 0 and participated in 3 of 3 tracked venture rounds · 3 in the last 12 months
| Date | Company | Event | Role | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|---|---|
| Oct 10, 2026 | Atrium Therapeutics | funding round | Participated | $50M | — | Pulse 2.0 | |
| Oct 6, 2026 | Multiply Labs | Series B | Participated | $75M | — | Lingotto Investment ManagementunverifiedCasdin CapitalunverifiedLux CapitalunverifiedFifty YearsunverifiedFounders FundunverifiedPatrick Soon-Shiong / NantWorksAstraZenecaTeradyneStrange Ventures+1 more | Business Wire |
| Jun 30, 2026 | Flare Therapeutics | Series C | Participated | $85M | — | Pulse story |
Sector / Stage Activity
Co-Investors
11Similar Firms
overlapping sector, stage or regionValue Add Research
Latest Pulse
- Oct 10, 2026Atrium Therapeutics Raises $50M For Heart DrugsAtrium Therapeutics raised a $50 million private placement priced at market to fund two RNA-therapy programs for rare heart conditions through 2028.→
- Oct 6, 2026Multiply Labs Raises $75M To Automate Drug ManufacturingMultiply Labs raised a $75 million Series B led by Dr. Patrick Soon-Shiong's NantWorks to scale robotic systems that automate biologics manufacturing, pushing its total funding past $100 million.→
- Jun 30, 2026Flare Therapeutics Raises $85M, Names New CEOFlare Therapeutics closed an $85 million insider-led Series C and named Anna Protopapas CEO, funding its first-in-class ARON-targeting degrader for prostate cancer toward a Phase 1A trial expected in Q3 2026.→
Casdin Capital FAQ
What companies has Casdin Capital invested in?
Casdin Capital's portfolio includes Atrium Therapeutics, Multiply Labs, Flare Therapeutics.
Who does Casdin Capital co-invest with most?
In the rounds Value Add tracks, Casdin Capital most often invests alongside Boxer Capital (1 shared deal), Eli Lilly (1 shared deal), Eli Lilly and Company (1 shared deal), Founders Fund (1 shared deal), GordonMD Global Investments (1 shared deal).
Sources & methodologyshow
- Business Wireprimary source1 fact
- GlobeNewswireprimary source1 fact
- Pulse 2.0Value Add VC data1 fact
Figures are labelled Reported (a source states it), Estimated, Derived (computed from other facts) or Rumored (in talks / unconfirmed). Rumors never replace a confirmed figure. Each figure keeps its own as-of date; history is preserved rather than overwritten.